Drug details

Poteligeo (mogamulizumab-kpkc injection)

type of CCR4 Inhibitors

Poteligeo (mogamulizumab-kpkc) injection is a CC chemokine receptor type 4 (CCR4)-directed monoclonal antibody indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• nausea,
• itching,
• diarrhea,
• fever,
• skin rash,
• chills,
• cough,
• sore throat,
• painful mouth sores,
• shortness of breath
• stomach pain, and
• blistering or peeling of the skin,

The following drugs are related to Poteligeo, either as a replacement or used together:

• Afinitor (everolimus tablets)
• Afinitor Disperz (everolimus tablets)
• Akynzeo (netupitant and palonosetron capsules)
• Alecensa (alectinib capsules)
• Alimta (pemetrexed)
• Aliqopa (copanlisib for injection, for intravenous use)
• Arimidex (anastrozole)
• Aranesp (darbepoetin alfa)
• Aredia (pamidronate disodium)
• Besponsa (inotuzumab ozogamicin injection)
• Breyanzi (lisocabtagene maraleucel suspension for intravenous infusion)
• Riabni (rituximab-arrx injection)